Abstract
Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Keywords: calcitriol, cancer, microRNA, vitamin D.
Current Gene Therapy
Title:Vitamin D and miRNAs in Cancer
Volume: 14 Issue: 4
Author(s): Yingyu Ma, Donald L. Trump and Candace S. Johnson
Affiliation:
Keywords: calcitriol, cancer, microRNA, vitamin D.
Abstract: Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Export Options
About this article
Cite this article as:
Ma Yingyu, Trump L. Donald and Johnson S. Candace, Vitamin D and miRNAs in Cancer, Current Gene Therapy 2014; 14 (4) . https://dx.doi.org/10.2174/1566523214666140612153537
DOI https://dx.doi.org/10.2174/1566523214666140612153537 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Qigefang Inhibits Migration, Invasion, and Metastasis of ESCC by Inhibiting Gas6/Axl Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Transcription/Expression of KLRB1 Gene as A Prognostic Indicator in Human Esophageal Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?
Anti-Cancer Agents in Medicinal Chemistry Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Review of Childhood Obesity (Balar Athidhoola Rogam) in Traditional Siddha Indian Medicine
Current Traditional Medicine Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews Finding Novel Anti-carcinomas Compounds by Targeting SFRP4 Through Molecular Modeling, Docking and Dynamic Simulation Studies
Current Computer-Aided Drug Design High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
Anti-Cancer Agents in Medicinal Chemistry